Position in NVAX
as of Jun 30, 2026
· filed Jul 27, 2026
Position Value
$2,826
+$384 QoQ
Shares Held
300
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#217
of 263 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Hilton Head Capital Partners, LLC holds $458,136 across 30 Biotechnology names. NVAX ranks #17 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
4,351 | $81,146 | |
| 2 | DYN |
Dyne Therapeutics, Inc.
|
3,420 | $75,958 | |
| 3 | OCUL |
Ocular Therapeutix, Inc
|
6,867 | $67,433 | |
| 4 | TYRA |
Tyra Biosciences, Inc.
|
2,024 | $64,646 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
650 | $48,412 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
50 | $24,836 | |
| 7 | IRD |
Opus Genetics, Inc.
|
4,472 | $18,379 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
83 | $15,544 |
All Filings in NVAX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,826 | 300 | Shares | Sole | 2026-07-27 | |
| 2026-03-31 | $2,442 | 300 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $2,016 | 300 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||